Rapport Therapeutics, Inc. (NASDAQ: RAPP) is generating significant buzz in the biotechnology sector with its promising pipeline of treatments for central nervous system (CNS) disorders. As a clinical-stage biopharmaceutical company, Rapport is spearheading innovative research into small molecule medicines, with a particular focus on diseases such as focal epilepsy and peripheral neuropathic pain. For investors eyeing opportunities in the healthcare sector, Rapport Therapeutics presents a compelling case with an impressive potential upside of 83.13%.

#### Market Position and Financial Health

Positioned in the United States and operating within the robust biotechnology industry, Rapport Therapeutics has carved out a niche in CNS…